Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT05416931
Previous Study | Return to List | Next Study

ACD440 Gel in Peripheral Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05416931
Recruitment Status : Recruiting
First Posted : June 14, 2022
Last Update Posted : June 24, 2022
Information provided by (Responsible Party):
AlzeCure Pharma

Brief Summary:
This is a double-blind, randomized, placebo-controlled crossover outpatient study in patients with peripheral neuropathic pain with allodynia or hyperalgesia to cold, heat, brush and/ or pinprick stimulation. Patients will in random order receive ACD440 Gel or placebo treatment twice daily for 7 days, topically applied to the painful area. This is followed by a 2-week washout period, then receive the alternate treatment.

Condition or disease Intervention/treatment Phase
Peripheral Neuropathic Pain Drug: ACD440 Gel 14mg/g Drug: Placebo Gel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Crossover Study to Explore the Effects of ACD440 in Patients With Peripheral Neuropathic Pain With Sensory Hypersensitivity.
Actual Study Start Date : June 20, 2022
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : February 2023

Arm Intervention/treatment
Experimental: ACD440 Gel 14mg/g
Topically applied to painful neuropathic area twice daily for 7 days
Drug: ACD440 Gel 14mg/g
Topical application to painful area

Placebo Comparator: Placebo Gel
Topically applied to painful neuropathic area twice daily for 7 days
Drug: Placebo Gel
Topical application to painful area

Primary Outcome Measures :
  1. Stimulus evoked pain [ Time Frame: Change from baseline to Day 7 ]

    Pain evoked by stimulus: brushing pain, pressure pain or cold pain, subitems 8-10 of the Neuropathic Pain Symptom Inventory (NPSI).

    Intensity is scored on a scale from 0-10, where 0 means no pain and 10 means worst pain possible.

Secondary Outcome Measures :
  1. Symptoms of neuropathic pain [ Time Frame: Baseline and day 7 of the respective treatment period ]
    Intensity of symptoms of neuropathic pain assessed by the Neuropathic Pain Symptom Inventory (NPSI). The NPSI total score ranges from 0 to 50, where 0 depicts absence of pain and 50 is the worst score.

  2. Intensity of spontaneous pain on a numerical rating scale (NRS) [ Time Frame: Baseline and day 7 of the respective treatment period ]
    Spontaneous pain intensity during the last 24-hours, rated on a Numerical Rating Scale (NRS), where score range from 0-10, where 0 means no pain and 10 means worst pain possible.

  3. Patient Global Impression of Change (PGIC) [ Time Frame: Day 7 of the respective treatment period ]
    Rating on a 7-step verbal scale: much worse - worse - a little worse - no difference - a little better - better - much better.

Other Outcome Measures:
  1. Safety and Tolerability [ Time Frame: From enrollment through study completion on Day 42. ]
    Incidence of Treatment-Emergent Adverse Events as assessed by spontaneous reporting and by laboratory measures and electrocardiogram (ECG)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent prior to any study related procedures.
  2. Male or female between 18 and 80 years of age, inclusive, at the screening visit.
  3. Diagnosed with painful peripheral polyneuropathy (PNP), including etiologies behind the PNP being but not limited to painful peripheral polyneuropathy, peripheral mononeuropathy, postherpetic neuralgia (PHN), chemotherapy induced neuropathic pain, nerve injury pain, chronic postoperative neuropathic pain with a history of 6 months to 7 years prior to the screening visit.
  4. Hypersensitivity to one or more of the following sensory stimuli: mechanical (brush or pinprick), thermal (cold).
  5. Pain intensity of 4-7 out of 10 on a numerical rating scale (NRS) to any of the sensory stimuli mentioned in inclusion criterion
  6. The area of sensory hypersensitivity can be up to a total of 600 cm2.
  7. Subjects with reproductive potential will need to use accepted and highly effective means of contraception from study entry until at least 6 weeks for females (women of childbearing potential, WOCP) and 3 months for males after IMP discontinuation (as per the Clinical Trials Facilitation and Coordination Group (CTFG) guidelines).

Exclusion Criteria:

  1. Participated in a clinical study and received active drug in such a study within 30 days or 5 study drug half-lives, whichever the longest, prior to screening visit.
  2. A body mass index (BMI) <18.5 kg/m2 or >35 kg/m2.
  3. Serum aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) levels >2 times the upper limit of normal (ULN) at the screening assessments.
  4. Evidence and/or history of any clinically significant neurological disease, other systemic diseases or conditions potentially interfering with study assessments, as judged by the investigator.
  5. Have another concomitant pain condition with an intensity of ≥4 out of 10, for which, as judged by the principal investigator, pain ratings may interfere with study assessments.
  6. Have a Hospital Anxiety and Depression Scale (HADS) score of 15 or above.
  7. Active Human immunodeficiency virus (HIV) or ongoing hepatitis B and/or C.
  8. Ongoing infection with fever (i.e., body temperature >38.0 ˚C).
  9. Known history of hypersensitivity to components of the study drug or a history of anaphylactic reactions.
  10. Malignancy within the past 5 years. In situ basal cell carcinoma and in situ squamous cell carcinoma of the skin are exempt, unless localised to the area of neuropathic pain.
  11. History of dermatological diseases including rosacea, syphilitic and tuberculotic reactions.
  12. Open wounds, scars, as well as extended tattoos on intended treatment areas.
  13. Skin infections, acne, skin inflammation, eczema, or other dermatological disorders in the intended treatment area.
  14. Pregnant or breastfeeding female or female who is planning pregnancy during the study period.
  15. Could be negatively affected by participation in the study, as judged by the investigator.
  16. Diagnosed with any significant psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM) 5® criteria, including drug abuse or dependency.
  17. Daily intake of opioids at a daily dose of more than 60 morphine equivalents.
  18. Use of Lidocaine patches within 7 days prior to randomisation until the follow-up visit.
  19. Use of Capsaicin patches within 4 months prior to randomisation until the follow-up visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05416931

Layout table for location contacts
Contact: Märta Segerdahl, MD; PhD +46736808898

Layout table for location information
Akademiska sjukhuset Recruiting
Uppsala, Sweden, 75185
Contact: Miclescu         
Sponsors and Collaborators
AlzeCure Pharma
Layout table for additonal information
Responsible Party: AlzeCure Pharma Identifier: NCT05416931    
Other Study ID Numbers: D8000-003
First Posted: June 14, 2022    Key Record Dates
Last Update Posted: June 24, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations